Scholars Central

Conference abstractPublished 2 Mar 2020

Enhanced tumor toxicity and reduced off-target toxicity by pretargeting mammary carcinoma with bispecific antibody complexes and dual polymer-pro- drug conjugates

Authors: Ban An Khaw, Na Yoon Kim, Prashant Bhattarai

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: Conventional chemotherapy is associate with severe off target toxicities. Pretargeting of high specific activity Polymer-Pro-Drug Conjugates (PPDCs) should reduce off-target toxicity and increase therapeutic efficacy. We now report enhanced therapeutic efficacy in a murine mammary carcinoma model pretargeted with Bispecific Botinylated anti-DTPA Antibody Complexes (BSAbC) and targeting with single or double PPDCs containing Doxorubicin (Dox) or Paclitaxel (Ptxl). No hematological- nor cardio-toxicity were seen in animals treated with PPDCs. Methods: Biotin-anti-DTPA antibody BSAbC was used to pretarget murine mammary carcinoma 4T1, that over-express biotin receptors grown in Balb/C mice. Experiment treatments were as follows: placebo, Dox, Ptxl, pretargeting with BSAbC followed by DOX-PPDCs, Ptxl-PPDCs, or combination of both PPDCs injected weekly. Tumor volumes were measured daily. Then, tumors were harvested, weighed and TUNEL staining was performed to assess apoptosis. Blood samples were obtained for H &E staining to determine hematological toxicities. Hearts from experimental animals were analyzed by fluorescence microscopy for Dox cardiotoxicity. Results: Maximal tumor growth suppression was observed in the combination PPDC treatment group (67mg). Individual DOX-PPDCs or Ptxl-PPDCs treatment were better than Dox or Ptxl treated tumors. The placebo group tumor size was 670 mg. The extent of apoptosis by TUNEL staining was inversely proportional to with tumor size. Fluorescence microscopy showed that Dox treatment had Dox fluorescence in the myocardium whereas hearts from pretargeted PPDC groups showed no Dox accumulation. There was no hematological toxicity in single PPDC or dual PPDC therapy groups whereas Dox and Ptxl treatment groups showed toxicities (p<0.05-0.01 respectively). Conclusion: Biotin receptor expressing murine 4T1 carcinoma could be pretargeted and targeted with single or dual PPDCs to obtain optimal tumor regression. Both cardiotoxicity and hematological toxicities were not observed following treatment with PPDCs. This therapeutic approach could provide highly effective cancer therapy with no off-targeted toxicity. PDF HTML Digital File

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Neurology and Clinical Neuroscience.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology and Clinical Neuroscience
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Ban An Khaw”
  • BylineArticles whose byline prints “Na Yoon Kim”
  • BylineArticles whose byline prints “Prashant Bhattarai”